Northwire Canada EditionSaturday, July 18, 2026
Northwire
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Financings

Manulife Becomes First Canadian Insurer to Offer the Galleri(TM) Multi-Cancer Early Detection Test by GRAIL

MFC · Price

Executive Summary

  • Manulife Canada becomes the first Canadian insurer to provide GRAIL’s Galleri® multi‑cancer early detection test to eligible life‑insurance customers through its Vitality program.
  • The test will be available at Medcan clinics in Toronto and Oakville for members aged 50 + at a reduced cost under the Manulife Vitality Plus plan.
  • The partnership expands Manulife’s health‑wellness portfolio and aligns with its broader collaboration with GRAIL that began in 2022 via John Hancock (U.S.).

Key Details

  • Partnership: Manulife Canada + Medcan (official Canadian provider of Galleri) to deliver the test.
  • Eligibility: Life‑insurance customers enrolled in the Manulife Vitality program, aged 50 years or older.
  • Access Points: Medcan clinics – Toronto (150 York St.) and Oakville (2275 Upper Middle Rd.).
  • Cost Structure: Offered at a reduced price through the Manulife Vitality Plus program (specific pricing not disclosed).
  • Test Capability: Single blood draw detecting > 50 cancer types; clinical program includes > 385,000 participants.
  • Clinical Evidence: PATHFINDER‑2 study (Oct 2024) showed > 7‑fold increase in detection when Galleri is added to standard screenings for breast, cervical, colorectal and lung cancers.
  • Strategic Context: Builds on Manulife’s existing collaboration with GRAIL via John Hancock (U.S.) launched in 2022; part of broader effort to integrate innovative health technologies into insurance offerings.
  • Quotes:
  • “Manulife is proud to be at the forefront of innovation… offering this groundbreaking screening test to our customers.” – Naveed Irshad, President & CEO, Manulife Canada.
  • “We’re proud to collaborate with Manulife to introduce this groundbreaking screening test…” – Shaun Francis, Chair & CEO, Medcan.
  • Public Health Impact: Aims to complement Canada’s universal healthcare screening programs and improve early‑cancer detection outcomes.

Notable Quotes

  • “Cancer has touched nearly every Canadian in some way… we’re giving Canadians a stronger start in the fight—one rooted in early detection and proactive care.” – Naveed Irshad, President & CEO, Manulife Canada
  • “This initiative is about looking ahead – exploring how we can responsibly expand access to promising technologies…” – Paul Savage, Head of Individual Insurance, Manulife Canada
Read the original news release →

More from MANULIFE FINANCIAL CORPORATION